Evidence map›Paper›PMID 32298048›Full record

Observational studyInfluenza and other respiratory viruses2020

Influenza vaccine effectiveness among outpatients in the US Influenza Vaccine Effectiveness Network by study site 2011-2016.

Goundappa K Balasubramani, Mary Patricia Nowalk, Theresa M Sax, Joe Suyama, Emily Bobyock, Charles R Rinaldo, Emily T Martin, Arnold S Monto, Michael L Jackson, Manjusha J Gaglani and 3 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Influenza and other respiratory viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Goundappa K BalasubramaniDepartment of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Mary Patricia NowalkDepartment of Family Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0002-1702-2690
Theresa M SaxDepartment of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Joe SuyamaDepartment of Emergency Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Emily BobyockDepartment of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Charles R RinaldoDepartment of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Emily T MartinSchool of Public Health, University of Michigan, Ann Arbor, MI, USA.
Arnold S MontoSchool of Public Health, University of Michigan, Ann Arbor, MI, USA.
Michael L JacksonKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Manjusha J GaglaniBaylor Scott & White Health, Texas A&M University College of Medicine, Temple, TX, USA.
Brendan FlanneryCenters for Disease Control and Prevention, Atlanta, GA, USA.
Jessie R ChungCenters for Disease Control and Prevention, Atlanta, GA, USA.
Richard K ZimmermanDepartment of Family Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
University of Pittsburgh · USCenters for Disease Control and Prevention · USUniversity of Michigan · USBaylor Scott & White Health · USKaiser Permanente Washington Health Research Institute · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
Prospective annual estimates of influenza vaccine effectiveness and burden of diseaseU01IP001037 · IP · KAISER FOUNDATION RESEARCH INSTITUTE · PI JACKSON, MICHAEL L · 2016 to 2020
$7.8M
Core_plus_Option_A_B_Proposal for Influenza Vaccine Effectiveness ResearchU01IP000474 · IP · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MONTO, ARNOLD S · 2011 to 2015
$6.2M
Core_plus Option_A_C_Influenza Surveillance and Vaccine Effectiveness in a LargeU01IP000467 · IP · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZIMMERMAN, RICHARD K · 2011 to 2015
$5.9M
Core_RT-PCR based Case-Control: Apt Measure of Influenza Vaccine EffectivenessU01IP000473 · IP · SCOTT AND WHITE MEMORIAL HOSPITAL · PI GAGLANI, MANJUSHA · 2011 to 2015
$4.0M
NCATS NIH HHS UL1 TR001857NCIRD CDC HHS 1-5U01 IP000473NCIRD CDC HHS 1U01P000474NCIRD CDC HHS 5U01 IP001037NCIRD CDC HHS U01 IP000467NCIRD CDC HHS U01 IP000473NCIRD CDC HHS U01 IP001034NCIRD CDC HHS U01 IP001035NCIRD CDC HHS U01 IP001039NIH HHS 1UL1 TR001857
6 · The paper itself

Abstract

backgroundInfluenza vaccination is recommended for all US residents aged ≥6 months. Vaccine effectiveness (VE) varies by age, circulating influenza strains, and the presence of high-risk medical conditions. We examined site-specific VE in the US Influenza VE Network, which evaluates annual influenza VE at ambulatory clinics in geographically diverse sites.

methodsAnalyses were conducted on 27 180 outpatients ≥6 months old presenting with an acute respiratory infection (ARI) with cough of ≤7-day duration during the 2011-2016 influenza seasons. A test-negative design was used with vaccination status defined as receipt of ≥1 dose of any influenza vaccine according to medical records, registries, and/or self-report. Influenza infection was determined by reverse-transcription polymerase chain reaction. VE estimates were calculated using odds ratios from multivariable logistic regression models adjusted for age, sex, race/ethnicity, time from illness onset to enrollment, high-risk conditions, calendar time, and vaccination status-site interaction.

resultsFor all sites combined, VE was statistically significant every season against all influenza and against the predominant circulating strains (VE = 19%-50%) Few differences among four sites in the US Flu VE Network were evident in five seasons. However, in 2015-16, overall VE in one site was 24% (95% CI = -4%-44%), while VE in two other sites was significantly higher (61%, 95% CI = 49%-71%; P = .002, and 53%, 95% CI = 33,67; P = .034).

conclusionWith few exceptions, site-specific VE estimates aligned with each other and overall VE estimates. Observed VE may reflect inherent differences in community characteristics of the sites and highlights the importance of diverse settings for studying influenza vaccine effectiveness.

Indexed as

Vaccine PotencyAdolescentAdultAgedCase-Control StudiesChildChild, PreschoolFemaleHumansInfantInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza B virusInfluenza, HumanInfluenza VaccinesMaleInfluenza Vaccinesinfluenzainfluenza vaccinevaccine effectiveness

Identifiers

PMID32298048
PMCPMC7298285
OpenAlexW3016561011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.